We are maintaining our fair value estimate for Truist Financial at $47 per share. We value the firm at roughly 1.6 times tangible book value as of the end of 2024.

Truist Securities reiterated their Buy rating on Genmab A/S (NASDAQ:GMAB) with a steady price target of $50.00. The firm's analysts remain confident in the biotech company's prospects, particularly in ...

CFO Mark Hirschhorn reported a 36% year-over-year increase in subscription revenue to $37 million in Q4, noting strategic client deployments as the primary driver. He also emphasized significant cost ...

Chairman and CEO James Quincey highlighted a 7% comparable EPS growth for 2024, despite challenges such as double-digit currency headwinds and bottler refranchising. He noted robust organic revenue ...

Jefferies analyst Philip Ng adjusted the price target for Mohawk Industries (NYSE: NYSE:MHK), a leading flooring manufacturer ...

Discover Truist’s checking account features, fees, and benefits in our comprehensive review. Learn how to maximize perks and ...